Marinus Pharmaceuticals (NASDAQ:MRNS) Receives Overweight Rating from Cantor Fitzgerald

Marinus Pharmaceuticals (NASDAQ:MRNS)‘s stock had its “overweight” rating restated by investment analysts at Cantor Fitzgerald in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $13.00 price objective on the biopharmaceutical company’s stock.

Several other brokerages also recently weighed in on MRNS. StockNews.com upgraded Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, September 9th. LADENBURG THALM/SH SH downgraded shares of Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday, August 14th. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Marinus Pharmaceuticals in a research report on Wednesday, August 14th. Finally, Truist Financial reissued a “buy” rating and set a $10.00 target price on shares of Marinus Pharmaceuticals in a research report on Tuesday, June 18th. Five research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $10.25.

Marinus Pharmaceuticals Stock Performance

Shares of Marinus Pharmaceuticals stock opened at $1.55 on Monday. The company has a market capitalization of $85.15 million, a PE ratio of -0.59 and a beta of 1.13. The company has a 50-day simple moving average of $1.36 and a two-hundred day simple moving average of $2.94. Marinus Pharmaceuticals has a one year low of $1.05 and a one year high of $11.26. The company has a debt-to-equity ratio of 5.68, a quick ratio of 2.15 and a current ratio of 2.28.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.01). The firm had revenue of $8.06 million for the quarter, compared to the consensus estimate of $9.05 million. Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 493.14%. During the same quarter last year, the firm earned ($0.61) EPS. Research analysts expect that Marinus Pharmaceuticals will post -1.88 EPS for the current fiscal year.

Institutional Trading of Marinus Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Point72 DIFC Ltd purchased a new position in shares of Marinus Pharmaceuticals during the second quarter worth $28,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Marinus Pharmaceuticals during the 2nd quarter valued at about $64,000. AQR Capital Management LLC raised its stake in shares of Marinus Pharmaceuticals by 70.3% during the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 12,934 shares during the last quarter. Squarepoint Ops LLC acquired a new position in shares of Marinus Pharmaceuticals in the 2nd quarter valued at about $206,000. Finally, XTX Topco Ltd purchased a new stake in shares of Marinus Pharmaceuticals in the second quarter worth about $232,000. 98.80% of the stock is currently owned by institutional investors and hedge funds.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.